Aequus Pharmaceuticals Inc.

As of September 30, 2025, Aequus Pharmaceuticals Inc. has 132.63M shares outstanding.

These figures are as of September 30, 2025. The EV/Sales ratio of 6.55 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Aequus Pharmaceuticals Inc. trades at an EV/FCF ratio of 38.72, comparing the total takeover cost of the business to the cash it actually generates for all capital providers.

As of September 30, 2025, Aequus Pharmaceuticals Inc. maintains a current ratio of 0.03, meaning it holds 0.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -87.46, indicating conservative leverage, while an interest coverage ratio of -1.87 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended September 30, 2025. Return on assets (ROA) is negative at -124.52, reflecting losses generated across the asset base. Return on capital employed (ROCE) is 4.20, useful for judging operating efficiency across full business cycles. Inventory turnover of 7.59 indicates how many times Aequus Pharmaceuticals Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on May 20, 2025, Aequus Pharmaceuticals Inc.'s stock has declined approximately 75.00% over the past 52 weeks. The 50-day moving average sits at 0.01, while the 200-day moving average is 0.01.

Over the twelve months ended September 30, 2025, Aequus Pharmaceuticals Inc. posted a gross margin of 56.95, reflecting its pricing power and cost economics. The operating margin of -62.50 and net profit margin of -71.46 provide insight into operational efficiency.

As of September 30, 2025, Aequus Pharmaceuticals Inc. has an Altman Z-Score of -299.09, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.